Screen Shot 2017-03-06 at 5.15.58 PM.png
 
 

Miromatrix is a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs utilizing its patented perfusion decellularization/recellularization technology, as well as the development of next generation of acellular based products.

Technology

Revolutionizing Regenerative Medicine.

Perfusion Recellularization

Perfusion decellularized organs are the ideal template to support the growth and differentiation of cells into functional organs. Click here to learn how Miromatrix is utilizing its proprietary perfusion recellularization to engineer transplantable organs. 

Perfusion Decellularization

Organ regeneration begins with pristine decellularized extracellular matrix organ scaffolds.  Click here to learn more about our patented perfusion decellularization technology used in our whole organ regeneration programs and our FDA cleared products.


Organ ProgramS

Our goal is to eliminate the organ transplant waiting list.

Bioengineering a transplantable Liver  

End-stage liver disease (ESLD) is the 8th leading cause of death in the United States, accounting for 40,000 deaths annually.  The only curative therapy for ESLD is liver transplantation. Unfortunately, the success of liver transplantation has led to its greatest challenge, the shortage of available organs.  Nationally, about 16,000 patients per year are waiting for liver transplantation.  Two-thirds won’t receive a liver.  Our whole liver recellularization can change this, Click here to learn more.

 

Bioengineering a transplantable Heart

Globally, cardiovascular disease accounts for over 17 million deaths annually. Every year over 600,000 people die of heart disease in the United States and over 700,000 people have a heart attack. The need for new cardiovascular therapies are greater than ever, with more than 3,000 patients waiting for approximately 2,000 hearts per year. Click here to learn more about our progress as we work towards partial and full heart recellularization.



 

Bioengineering a transplantable Kidney

Over 400,000 individuals have end-stage kidney disease requiring hemodialysis in the United States, with approximately 100,000 individuals awaiting a kidney transplant.  Due to the chronic shortage of transplantable kidneys, less than 20,000 kidneys are transplanted annually.  The five-year survival rate for those on dialysis is ~35%.  The need for a new source of transplantable kidneys is greater than ever.  Click here to learn more about our path to engineering a fully recellularized kidney.  

 

 

We are working on other organ models that perfusion decellularization and recellularization may be applied to.  These include bone, lung, pancreas, brain, spine and other tissues.  


MIRODERM-navigation-background.png

MIRODERM® is a porcine liver-derived noncrosslinked acellular biologic wound matrix.  It is indicated for the management of wounds, including: diabetic foot; venous and pressure ulcers; surgical and trauma wounds; and more.  The MIRODERM Product Family includes:

 
MIROMESH-Main-Background.png

MIROMESH® is a non-crosslinked acellular surgical mesh that is derived from the highly vascularized porcine liver.  It is intended to be implanted to reinforce soft tissue and is also intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.

Click here to learn more about MIROMESH and our size offerings.  

 

Newsroom